Sanofi US

270 Albany Street
Cambridge
Massachusetts
02139
United States

Tel: 800-446-6267

About Sanofi US

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With more than 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, employs more than 17,000 professionals throughout the country. At Sanofi, we work for what really matters: Health.

150 articles with Sanofi US

FDA approves Toujeo® Max SoloStar®

3/27/2018

Max SoloStar holds more insulin than any other long-acting insulin pen
Ablynx Drug Fails Again in Mid-Stage Trial

3/26/2018

For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
Sanofi and Regeneron Slash Cost of New Cholesterol Drug Praluent

3/12/2018

Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.
Prevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs

3/8/2018

Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease.
Esperion's Cholesterol Drug Positive in PhIII Trial

3/7/2018

Esperion announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.
VCs Are Pouring Billions into Biotech in 2018

3/6/2018

While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
Sanofi and Regeneron Seek FDA Approval of Dupixent as Add-On Asthma Therapy

3/2/2018

Asthma patients may soon have a new treatment option.
Sanofi US Collaborates With Duke University And Massachusetts General Hospital On Big Data And Type 2 Diabetes

4/28/2016
Sanofi US To Return Auvi-Q (epinephrine injection, USP) Rights To Kaleo

2/24/2016
Pozen, Inc. And Sanofi US Mutually Agree To Terminate U.S. Partnership For PA8140/PA32540

12/1/2014
Sanofi US Launches Authorized Generic Version Of Eloxatin® (oxaliplatin Injection)

8/12/2014
Sanofi-Aventis (Massachusetts) Release: Allegra(R) and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures"

8/10/2011
Gov. Deval Patrick Meets with Sanofi-Aventis (Massachusetts), Genzyme Corporation CEOs to Discuss Job Losses

2/18/2011
Albany Molecular Research, Inc. Wtih Sanofi-Aventis (Massachusetts) Files Motion for Preliminary Injunction Prohibiting Dr. Reddy's Laboratories, Inc.'s from Distributing Generic Allegra-D(R) 24

3/23/2010
Cegedim Dendrite Announces Extension of Customer Relationship Management (CRM) Agreement with Sanofi-Aventis (Massachusetts)

3/15/2010
Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit - Carekit Offers Acne Patients Simple and Convenient Moisturizing Option

8/4/2009
Antisoma PLC Sells Oral Fludarabine to Sanofi-Aventis (Massachusetts) for $65 Million

5/12/2009
Sanofi-Aventis (New York) And Bristol-Myers Squibb Company Release: Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal

11/6/2008
Sanofi-Aventis (France)'s Acomplia Linked To 5 Deaths

6/4/2008
Sanofi-Aventis (New York) Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy First Phase III Study

5/27/2008